FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214897030> ?p ?o ?g. }

• W4214897030 endingPage "675" @default.
• W4214897030 startingPage "669" @default.
• W4214897030 abstract "To evaluate treatment satisfaction with galcanezumab as a patient-reported outcome measure (PROM) in migraine.Patients with ≥8 headache days/month that had failed at ≥3 medications were included. Demographic and medical history were collected. Patient´s satisfaction (effectiveness, safety, convenience, and global satisfaction [GS]) was assessed by the Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM-1.4©).We included 30 patients with migraine (76.7% chronic migraine). After 12 weeks of galcanezumab treatment, median monthly headache days (MHDs) decreased 11.5 (IQR 14.0) and median monthly migraine days (MMDs) 9.0 (IQR 7.5); at 24 weeks, the change was 15.0 (IQR 12.0) and 8.0 days (IQR 6.0). HIT-6 score decreased from 68.0 (IQR 7.5) to 54.0 (IQR 9.5) at 12 weeks (p < .001) and to 52.0 (IQR12.0) at 24 weeks (p < .001) and MIDAS from 60.0 (IQR 62.7) to 25.5 (IQR 41.2, p = .004) and 7.0 (IQR 18.5, p < .001), respectively. TSQM-1.4© at 12 weeks was higher compared to other preventive therapy in effectiveness (80.6/50.4, p < .001), convenience (83.3/66.7, p = .001), and GS (78.6/50.0, p < .001). These rates of satisfaction were similar at 24 weeks of galcanezumab treatment. Reductions in HIT-6 (r = -.444, p = .014), MIDAS (r = -.423, p = .020), MMDs (r = -.515, p = .004), and MHDs (r = -.477, p = .008) were associated significantly with GS at 12 weeks. This correlation was significantly associated with changes in HIT-6 and MHDs at 24 weeks.The results of this study suggest that migraine patients receiving galcanezumab are significantly more satisfied compared to other preventive therapies, associating treatment GS with meaningful reductions in frequency, impact, and disability caused by migraine." @default.
• W4214897030 created "2022-03-05" @default.
• W4214897030 creator A5006678797 @default.
• W4214897030 creator A5058313481 @default.
• W4214897030 creator A5069930303 @default.
• W4214897030 date "2022-03-03" @default.
• W4214897030 modified "2023-10-14" @default.
• W4214897030 title "Treatment satisfaction with calcitonin gene‐related peptide monoclonal antibodies as a new patient‐reported outcome measure: A real‐life experience in migraine" @default.
• W4214897030 cites W1984102564 @default.
• W4214897030 cites W1995973379 @default.
• W4214897030 cites W2114736324 @default.
• W4214897030 cites W2144317224 @default.
• W4214897030 cites W2166281097 @default.
• W4214897030 cites W2474097887 @default.
• W4214897030 cites W2765875427 @default.
• W4214897030 cites W2801085490 @default.
• W4214897030 cites W2805181790 @default.
• W4214897030 cites W2805937849 @default.
• W4214897030 cites W2886942140 @default.
• W4214897030 cites W2892069777 @default.
• W4214897030 cites W2895868360 @default.
• W4214897030 cites W2900579548 @default.
• W4214897030 cites W2901687990 @default.
• W4214897030 cites W2931739625 @default.
• W4214897030 cites W2981902069 @default.
• W4214897030 cites W2985571327 @default.
• W4214897030 cites W3007834801 @default.
• W4214897030 cites W3028566503 @default.
• W4214897030 cites W3034484255 @default.
• W4214897030 cites W3109623479 @default.
• W4214897030 cites W3120185602 @default.
• W4214897030 cites W3133794404 @default.
• W4214897030 cites W3154454412 @default.
• W4214897030 cites W3157961291 @default.
• W4214897030 doi "https://doi.org/10.1111/ane.13599" @default.
• W4214897030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35243611" @default.
• W4214897030 hasPublicationYear "2022" @default.
• W4214897030 type Work @default.
• W4214897030 citedByCount "4" @default.
• W4214897030 countsByYear W42148970302022 @default.
• W4214897030 countsByYear W42148970302023 @default.
• W4214897030 crossrefType "journal-article" @default.
• W4214897030 hasAuthorship W4214897030A5006678797 @default.
• W4214897030 hasAuthorship W4214897030A5058313481 @default.
• W4214897030 hasAuthorship W4214897030A5069930303 @default.
• W4214897030 hasBestOaLocation W42148970301 @default.
• W4214897030 hasConcept C118303440 @default.
• W4214897030 hasConcept C126322002 @default.
• W4214897030 hasConcept C141071460 @default.
• W4214897030 hasConcept C163170386 @default.
• W4214897030 hasConcept C170493617 @default.
• W4214897030 hasConcept C1862650 @default.
• W4214897030 hasConcept C2775944032 @default.
• W4214897030 hasConcept C2778541695 @default.
• W4214897030 hasConcept C2910587157 @default.
• W4214897030 hasConcept C71924100 @default.
• W4214897030 hasConcept C90924648 @default.
• W4214897030 hasConceptScore W4214897030C118303440 @default.
• W4214897030 hasConceptScore W4214897030C126322002 @default.
• W4214897030 hasConceptScore W4214897030C141071460 @default.
• W4214897030 hasConceptScore W4214897030C163170386 @default.
• W4214897030 hasConceptScore W4214897030C170493617 @default.
• W4214897030 hasConceptScore W4214897030C1862650 @default.
• W4214897030 hasConceptScore W4214897030C2775944032 @default.
• W4214897030 hasConceptScore W4214897030C2778541695 @default.
• W4214897030 hasConceptScore W4214897030C2910587157 @default.
• W4214897030 hasConceptScore W4214897030C71924100 @default.
• W4214897030 hasConceptScore W4214897030C90924648 @default.
• W4214897030 hasIssue "6" @default.
• W4214897030 hasLocation W42148970301 @default.
• W4214897030 hasLocation W42148970302 @default.
• W4214897030 hasOpenAccess W4214897030 @default.
• W4214897030 hasPrimaryLocation W42148970301 @default.
• W4214897030 hasRelatedWork W2591456584 @default.
• W4214897030 hasRelatedWork W2768357559 @default.
• W4214897030 hasRelatedWork W2883290297 @default.
• W4214897030 hasRelatedWork W2943954338 @default.
• W4214897030 hasRelatedWork W3111709648 @default.
• W4214897030 hasRelatedWork W3199883053 @default.
• W4214897030 hasRelatedWork W3207819762 @default.
• W4214897030 hasRelatedWork W3207849898 @default.
• W4214897030 hasRelatedWork W4281646781 @default.
• W4214897030 hasRelatedWork W4308877526 @default.
• W4214897030 hasVolume "145" @default.
• W4214897030 isParatext "false" @default.
• W4214897030 isRetracted "false" @default.
• W4214897030 workType "article" @default.